株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

脊髄性筋萎縮症 (SMA) :アジア太平洋地域の主要市場における疫学予測

Spinal Muscular Atrophy: Epidemiology Forecast in Asia-Pacific Markets to 2028

発行 GlobalData 商品コード 912106
出版日 ページ情報 英文 21 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.69円で換算しております。
Back to Top
脊髄性筋萎縮症 (SMA) :アジア太平洋地域の主要市場における疫学予測 Spinal Muscular Atrophy: Epidemiology Forecast in Asia-Pacific Markets to 2028
出版日: 2019年08月31日 ページ情報: 英文 21 Pages
概要

アジア太平洋地域の主要5ヶ国 (オーストラリア、中国、インド、韓国、日本) で脊髄性筋萎縮症 (SMA) と診断された患者数は、2018年の99,759人から、2028年の99,759人まで、AAR (年間成長率) で0.56%の増加が予測されています。

当レポートでは、アジア太平洋地域の主要5ヶ国における脊髄性筋萎縮症 (SMA) について調査分析し、最新の疫学予測について、体系的な情報を提供しています。

第1章 目次

第2章 エグゼクティブサマリー

第3章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界動向と歴史的動向
  • 予測手法
  • 脊髄性筋萎縮症 (SMA) の疫学予測
  • 議論

第4章 付録

図表

List of Tables

  • Table 1: Risk Factors and Comorbidities for SMA

List of Figures

  • Figure 1: 5GM, Diagnosed Prevalent Cases of SMA, N, Both Sexes, All Ages, 2018 and 2028
  • Figure 2: 5GM, Diagnosed Prevalence of SMA, %, Both Sexes, All Ages, 2018
  • Figure 3: 5GM, Sources Used and Not Used to Forecast the Diagnosed Prevalent
目次
Product Code: GDHCER214-19

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by degeneration of alpha motor neurons in the spinal cord, resulting in progressive proximal muscle weakness and paralysis. The most common form of SMA is 5q SMA, linked to chromosome 5q and its phenotype is classified into four grades of severity (type I, type II, type III, and type IV) based on age of onset and motor function achieved (Amico et al., 2011). Additionally, SMA type 0 is an uncommon form of very severe SMA with prenatal onset (Finkel et al., 2015). In rare cases SMA is also caused by the mutation in another gene and known as non-5q SMA (Verhaart, Robertson, Wilson, et al., 2017).

GlobalData epidemiologists utilized historical data obtained from Orphanet to build the forecast for the diagnosed prevalent cases of SMA in the 5GM. GlobalData epidemiologists applied the prevalence of SMA drawn from the above source to each country's population to calculate the number of estimated diagnosed prevalent cases for each subtype respectively.

The following data describes epidemiology of SMA. GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of SMA in the 5GM from 94,508 diagnosed prevalent cases in 2018 to 99,759 diagnosed prevalent cases in 2028, with an Annual Growth Rate (AGR) of 0.56% during the forecast period. India will have the highest number of diagnosed prevalent cases of SMA among the 5GM, while Australia will have the lowest. In the 5GM combined, type II SMA made up the highest proportion of diagnosed prevalent cases of SMA and type III made up the lowest proportion of diagnosed prevalent cases of SMA in 2018.

Scope

  • The Spinal Muscular Atrophy Epidemiology Report and Model provide an overview of the risk factors and global trends of Spinal Muscular Atrophy (SMA) in the five growth markets (5GM: Australia, China, India, South Korea, and Japan).
  • The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of SMA segmented by sex (for all ages) in these markets. The diagnosed prevalent cases of SMA are further segmented by type (type I, type II, type III and type IV). Additionally, the model includes a 10-year epidemiological forecast for the diagnosed prevalent cases of non-5q SMA.
  • The SMA epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 5GM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The SMA Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global SMA market.
  • Quantify patient populations in the global SMA market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SMA therapeutics in each of the markets covered.
  • Understand magnitude of SMA population by its type.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Spinal Muscular Atrophy: Executive Summary

  • 2.1 Related Reports
  • 2.2 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
    • 3.4.3 Forecast Assumptions and Methods - Diagnosed Prevalent Cases of SMA
  • 3.5 Epidemiological Forecast for SMA for Growth Markets (2018-2028)
    • 3.5.1 Diagnosed Prevalent Cases of SMA
    • 3.5.2 Sex-Specific Diagnosed Prevalent Cases of SMA
    • 3.5.3 Diagnosed Prevalent Cases of SMA by Type
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of Analysis
    • 3.6.3 Strengths of Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologists
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer
Back to Top